Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-04-01
2008-04-01
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S217060, C514S218000, C514S235800, C514S252140, C514S269000, C540S472000, C540S544000, C540S575000, C540S601000, C544S122000, C544S295000, C544S315000, C544S316000
Reexamination Certificate
active
07351700
ABSTRACT:
The present invention relates to compounds of formulawhereinX is —S— or —NH—;R3/R4together with the N-atom to which they are attached form a non aromatic 5, 6 or 7 membered ring, which optionally contains in addition to the N-atom one additional heteroatom selected from the group consisting of O, S and N, and wherein the ring is optionally substituted by hydroxy, lower alkyl, lower alkoxy, —NR2, —CONR2, —CO-lower alkyl or benzyl; or R3/R4form together with the N-atom to which they are attached a heterocyclic ring system, containing two or three rings and which optionally contains one or two additional heteroatoms selected from the group consisting of N and O and which has no more than 20 carbon atoms; andR, R1, R2, and R5are as defined herein and to pharmaceutically suitable acid addition salts thereof.It has been found that the compounds of the invention are active on the GABABreceptor and therefore are useful for the treatment of anxiety, depression, epilepsy, schizophrenia, cognitive disorders, spasticity and skeletal muscle rigidity, spinal cord injury, multiple sclerosis, amyotrophic lateral sclerosis, cerebral palsy, neuropathic pain and craving associated with cocaine and nicotine, psychosis, panic disorder, posttraumatic stress disorders and gastro-intestinal disorders.
REFERENCES:
patent: 6313146 (2001-11-01), Van Wagenen et al.
patent: WO 95/10506 (1995-04-01), None
patent: WO 01/56990 (2001-08-01), None
patent: WO 02/083651 (2002-10-01), None
patent: WO 03/090731 (2003-11-01), None
Hill et al., Nature, 290, 149-152, 1981.
Billinton et al., Trends Neurosci., 24, 277-282, 2001.
Bowery et al., Pharmacol. Rev. 54, 247-264, 2002.
Vacher et al.,, Curr. Drug Target, CNS Neurol. Disord. 2, 248-259, 2003.
Bettler, et al., Physiol Rev. 84, 835-867, 2004.
Kaupmann et al.,Nature, 386, 239-246, 1997.
Kaupmann et al., Nature, 396, 683-687, 1998.
Pin et al., Pharmaco. Ther. 98, 325-354, 2003.
Galvez et al., J. Biol. Chem., 275, 41166-41174, 2000.
Havlickova et al., Mol. Pharmacol. 62, 343-350, 2002.
Kniazeff et al.,J. Neurosci., 22, 7352-7361, 2002.
Schuler et al., Neuron, 31, 47-58, 2001.
Peters et al., Neurogenetics, 2, 47-54, 1998.
Mondabon et al., Am. J. Med. Genet 122B/1, 134, 2003.
Gassmann et al., J. Neurosci, vol. 24, pp. 6086-6097, 2004.
Misgeld et al., Prog. Neurobiol. 46, 423-462, 1995.
Enna et al., Life Sci, 62, 1525-1530, 1998.
McCarson et al., Neuropharmacology, 38, 1767-1773, 1999.
Brebner et al., Neuropharmacology, 38, 1797-1804, 1999.
Paterson et al., Psychopharmacology, 172, 179-186, 2004.
Breslow et al., Am. J. Psychiatry, 146, 353-356, 1989.
Drake et al., Ann. Pharmacother. 37, 1177-1181, 2003.
Bortolato et al., Psychopharmacology, 171, 322-330, 2004.
Urwyler et al., Mol. Pharmacol., 60, 963-971, 2001.
Pin et al., Mol. Pharmacol.,60, 881-884, 2001.
Binet et al., J Biol Chem., 279, 29085-29091, 2004.
Mombereau et al., Neuropsychopharmacology, vol. 29, 1050-1062, 2004.
Urwyler et al., J. Pharmacol. Exp. Ther., 307, 322-330, 2003.
Cryan et al., J Pharmacol Exp Ther., 310, 952-963, 2004.
Smith et al., Psychopharmacology, 173, 105-111, 2004.
Knoflach et al., Proc. Natl. Acad. Sci., USA, 98, 13402-13407, 2001.
Wichmann et al., Farmaco, 57, 989-992, 2002.
Hammerland et al., Mol. Pharmacol., 53, 1083-1088, 1998.
O'Brien et al., J. Pharmaco. Exp. Ther., 309, 568-577, 2004.
Schaffhauser et al., Mol. Pharmacol., 64, 798-810, 2003.
Porter et al., Br. J. Pharmacol. vol. 128, pp. 13-20 (1999).
Malherbe Pari
Masciadri Raffaello
Prinssen Eric
Spooren Will
Thomas Andrew William
Hoffmann-La Roche Inc.
Johnston George W.
Prior Kimberly J.
Rao Deepak
Rocha-Tramaloni Patricia S.
LandOfFree
Aminomethylpyrimidines as allosteric enhancers of the GABA B... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aminomethylpyrimidines as allosteric enhancers of the GABA B..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aminomethylpyrimidines as allosteric enhancers of the GABA B... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2752402